Description: <b>Dasatinib</b>, (brand name Sprycel) is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia and acute lymphoblastic leukemia.<br>
<p><b>Dasatinib</b> — Dasatinib is an orally administered, small-molecule, ATP-competitive multi-target tyrosine kinase inhibitor developed as BMS-354825 and marketed historically as Sprycel. It is formally classified as a second-generation BCR-ABL1/SRC-family kinase inhibitor and antineoplastic targeted therapy. Standard abbreviations include DAS and BMS-354825. Its highest-confidence clinical identity is treatment of Philadelphia chromosome-positive chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, while solid-tumor use remains investigational or context-dependent.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Direct inhibition of BCR-ABL1 kinase signaling in Philadelphia chromosome-positive leukemia, suppressing leukemic proliferation and survival signaling.</li>
<li>Inhibition of SRC-family kinases including SRC, LCK, YES, FYN, LYN, and HCK, reducing alternative kinase signaling, invasion, adhesion, migration, and some imatinib-resistance pathways.</li>
<li>Downstream suppression of STAT5, PI3K-AKT, and MAPK signaling in BCR-ABL1/SRC-dependent leukemic progenitors.</li>
<li>Secondary inhibition of c-KIT, PDGFRβ, and EPHA2, which may be relevant in selected tumor contexts but is not the dominant approved-use mechanism.</li>
<li>Senolytic activity in combination with quercetin, mainly through selective vulnerability of senescent cells; this is investigational and not an oncology-label mechanism.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Dasatinib is an oral drug with rapid absorption, high plasma protein binding, large apparent distribution volume, and short terminal half-life. Standard Sprycel/generic dasatinib exposure is pH-sensitive, so proton-pump inhibitors and H2 antagonists can reduce exposure; antacids require separation. A newer FDA-approved formulation, Phyrago, is designed to reduce this gastric-acid interaction constraint. Dasatinib is primarily metabolized by CYP3A4, so strong CYP3A4 inhibitors, inducers, grapefruit juice, and St. John’s wort are major PK constraints.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many leukemia-cell effects occur at low nanomolar concentrations and are clinically plausible. Some solid-tumor, migration, invasion, and high-concentration mechanistic findings may exceed or poorly model achievable tumor exposure, especially because dasatinib has high protein binding and short plasma half-life. This is concentration-driven and target-dependency-driven rather than field-based.</p>
<p><b>Clinical evidence status:</b> Approved targeted therapy with phase III evidence for Ph+ CML and established use in Ph+ ALL. Evidence in solid tumors is mostly preclinical, phase I/II, negative, or biomarker-dependent adjunct investigation. AD/senolytic use is early human proof-of-concept with dasatinib plus quercetin and is not approved disease-modifying therapy.</p>
<h3>Dasatinib Mechanistic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>BCR-ABL1 kinase addiction</td>
<td>↓ BCR-ABL1 signaling; ↓ proliferation; ↑ apoptosis in Ph+ leukemia</td>
<td>↔ in BCR-ABL1-negative cells except off-target kinase effects</td>
<td>P,R,G</td>
<td>Core leukemia-selective cytostatic and cytotoxic effect</td>
<td>Highest clinical relevance in Ph+ CML and Ph+ ALL; target presence is decisive.</td>
</tr>
<tr>
<td>2</td>
<td>SRC-family kinase signaling</td>
<td>↓ SRC, LYN, HCK, LCK, YES, FYN signaling; ↓ invasion and survival signaling</td>
<td>↓ immune-cell and platelet signaling possible</td>
<td>P,R,G</td>
<td>Blocks alternative oncogenic kinase signaling and some resistance pathways</td>
<td>Important for imatinib-resistant signaling and solid-tumor biology, but clinical benefit outside Ph+ leukemia is less consistent.</td>
</tr>
<tr>
<td>3</td>
<td>STAT5 survival signaling</td>
<td>↓ pSTAT5 downstream of BCR-ABL1 and SRC-family kinases</td>
<td>↓ cytokine and T-cell signaling possible</td>
<td>R,G</td>
<td>Reduces transcriptional survival programs</td>
<td>Mechanistically central in CML progenitors; contributes to apoptosis and reduced colony formation.</td>
</tr>
<tr>
<td>4</td>
<td>PI3K-AKT and MAPK signaling</td>
<td>↓ AKT and ↓ MAPK signaling in dependent leukemia progenitors</td>
<td>↔ or ↓ growth-factor signaling depending on cell type</td>
<td>R,G</td>
<td>Suppresses proliferation and anti-apoptotic signaling</td>
<td>Downstream effect rather than primary binding target; context-dependent in non-leukemia tumors.</td>
</tr>
<tr>
<td>5</td>
<td>c-KIT PDGFRβ EPHA2 kinase inhibition</td>
<td>↓ receptor kinase signaling where target-dependent</td>
<td>↓ normal stromal, vascular, hematopoietic, or progenitor signaling possible</td>
<td>P,R,G</td>
<td>Broadens kinase inhibition spectrum</td>
<td>Mechanistically real but not the main basis of approved use.</td>
</tr>
<tr>
<td>6</td>
<td>Cell adhesion migration and invasion</td>
<td>↓ migration; ↓ invasion; ↓ metastatic behavior markers in some solid-tumor models</td>
<td>↓ immune-cell trafficking and platelet function possible</td>
<td>G</td>
<td>Anti-invasive and cytostatic effect</td>
<td>High preclinical relevance; weaker clinical translation in unselected solid tumors.</td>
</tr>
<tr>
<td>7</td>
<td>Chemo sensitization</td>
<td>↑ sensitivity in selected combinations and biomarker contexts</td>
<td>↑ toxicity risk possible due to myelosuppression and bleeding</td>
<td>G</td>
<td>Adjunct pathway blockade</td>
<td>Combination use requires disease-specific evidence; not broadly generalizable.</td>
</tr>
<tr>
<td>8</td>
<td>Radiosensitization</td>
<td>↑ radiosensitivity reported in some SRC-dependent preclinical models</td>
<td>↑ normal-tissue radiosensitivity or marrow toxicity possible</td>
<td>G</td>
<td>Potential adjunct radiosensitizer</td>
<td>Not a standard approved radiosensitizer; clinical use should be considered investigational.</td>
</tr>
<tr>
<td>9</td>
<td>Immune and platelet signaling</td>
<td>↔ indirect antitumor effects; may alter immune microenvironment</td>
<td>↓ T-cell receptor signaling; ↓ platelet function; ↑ bleeding risk</td>
<td>P,R,G</td>
<td>On-target normal-cell pharmacology</td>
<td>Clinically important safety axis, especially bleeding, infection risk, and immune modulation.</td>
</tr>
<tr>
<td>10</td>
<td>ROS NRF2 mitochondria</td>
<td>↔ or context-dependent changes; not a core dasatinib mechanism</td>
<td>↔ or context-dependent stress response</td>
<td>G</td>
<td>Secondary stress-response modulation</td>
<td>Do not rank as a primary pathway unless a specific model demonstrates ROS-linked cytotoxicity.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>Target-negative tumors often show limited response despite kinase inhibition</td>
<td>Myelosuppression, pleural effusion, pulmonary hypertension, QT risk, bleeding, hepatotoxicity, pregnancy risk</td>
<td>G</td>
<td>Limits broad repurposing</td>
<td>Clinical translation depends on Ph+ status, kinase dependency, formulation, acid-suppression use, CYP3A4 interactions, and tolerability.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
<p><b>Dasatinib in Alzheimer’s disease</b> — Dasatinib is not an approved AD therapy. Its AD relevance is mainly as part of the investigational senolytic combination dasatinib plus quercetin, where intermittent dosing is intended to reduce senescent-cell burden and senescence-associated inflammatory signaling. Current evidence is early-stage human feasibility and biomarker work, not established cognitive efficacy.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Senolytic elimination of senescent cells in combination with quercetin, potentially reducing senescence-associated secretory phenotype signaling.</li>
<li>Reduction of neuroinflammatory and peripheral inflammatory senescence biomarkers, if senolytic activity translates into CNS-relevant exposure.</li>
<li>Possible effects on glial senescence and vascular/neurovascular dysfunction, still investigational.</li>
<li>PK limitation: dasatinib CNS exposure and intermittent dosing may constrain direct brain-target engagement.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> AD protocols use intermittent oral dasatinib with quercetin rather than continuous oncology dosing. The key translational question is whether adequate CNS exposure and senescent-cell selectivity occur without unacceptable toxicity in older adults.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Senolytic effects are concentration- and cell-state-dependent. In-vitro senescent-cell killing does not automatically imply achievable, selective CNS clearance in humans.</p>
<p><b>Clinical evidence status:</b> Early human phase I and pilot studies only. Phase II randomized testing has been registered, but dasatinib plus quercetin remains investigational for AD and mild cognitive impairment.</p>
<h3>Dasatinib AD Senolytic Profile</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Senescent-cell survival signaling</td>
<td>↓ senescent-cell viability with dasatinib plus quercetin</td>
<td>G</td>
<td>Senolytic clearance</td>
<td>Combination-dependent; dasatinib alone should not be treated as a validated AD senolytic regimen.</td>
</tr>
<tr>
<td>2</td>
<td>SASP inflammatory signaling</td>
<td>↓ senescence-associated inflammatory mediators (context-dependent)</td>
<td>G</td>
<td>Potential neuroinflammation reduction</td>
<td>Human evidence is biomarker-oriented and preliminary.</td>
</tr>
<tr>
<td>3</td>
<td>Glial and vascular senescence</td>
<td>↓ pathological senescence burden (model-dependent)</td>
<td>G</td>
<td>Potential support of brain microenvironment</td>
<td>Requires demonstration of CNS exposure and clinically meaningful target engagement.</td>
</tr>
<tr>
<td>4</td>
<td>Cognition and function</td>
<td>↔ or uncertain</td>
<td>G</td>
<td>No established disease-modifying effect</td>
<td>Existing studies are too small or exploratory to establish cognitive benefit.</td>
</tr>
<tr>
<td>5</td>
<td>Clinical Translation Constraint</td>
<td>↑ safety monitoring burden; ↔ efficacy unproven</td>
<td>G</td>
<td>Limits AD translation</td>
<td>Older adults may be vulnerable to cytopenias, bleeding, fluid retention, drug interactions, and infection risk.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>